These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 30270065)

  • 41. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Schreuder MM; Hamkour S; Siegers KE; Holven KB; Johansen AK; van de Ree MA; Imholz B; Boersma E; Louters L; Bogsrud MP; Retterstøl K; Visseren FLJ; Roeters van Lennep JE; Koopal C
    Atherosclerosis; 2023 Nov; 384():117117. PubMed ID: 37080805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
    Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists).
    Wong ND; Bang M; Block RC; Peterson ALH; Karalis DG
    Am J Cardiol; 2021 Aug; 152():57-62. PubMed ID: 34147211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Lalić K; Rajković N; Popović L; Lukač SS; Stošić L; Rasulić I; Lalić NM
    Atherosclerosis; 2018 Oct; 277():298-303. PubMed ID: 30270062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Shek A; Alieva R; Kurbanov R; Hoshimov S; Nizamov U; Abdullaeva G; Nagay A
    Atherosclerosis; 2018 Oct; 277():524-529. PubMed ID: 30270094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 60. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.